Health Equity and the Cost of Novel Treatments for Alzheimer’s Disease and AD-Related Dementias

Letter of Intent: September 29, 2023
Application: October 31, 2023

This NOFO invites applications to address health equity, drug costs, and access to new therapeutics for people living with AD/ADRD. Applicants must identify preferences for pharmacological treatment among racial and ethnic minorities living with AD/ADRD, assess whether cost barriers to pharmacological care exist for these groups, and quantify expenditures and HRQoL among people interested in receiving novel drugs to treat AD/ADRD.

Research Objectives
The goals of this NOFO are to identify whether cost-associated barriers to receiving novel therapeutics exist for racial and ethnic minority people living with AD/ADRD, and to evaluate the cost- effectiveness and health equity implications of new therapeutics in these populations. Studies proposed under this NOFO must clearly identify sub-population(s) to be engaged and methods for recruitment. Additionally, studies must provide a scientific rationale for selecting specific sub-populations. Investigators must conduct research to understand how, why, and for whom novel drugs are recommended and prescribed; who receives novel drugs; how long drugs are taken; how much novel drugs cost patients and caregivers in out-of-pocket payments, and the real-world health-related quality of life and well-being impacts of receiving novel drugs. This NOFO will support new research projects that conduct rigorous stakeholder engagement efforts and develop model parameters using both stakeholder input and quantitative data.

For more information, please see the opportunity announcement website.